Evelo Biosciences

Evelo Biosciences is a clinical-stage biotechnology company focused on developing novel therapies for the treatment of a range of diseases. The company's approach is based on the modulation of the gut microbiome, which is the collection of bacteria and other microorganisms that live in the human gut. Evelo believes that by targeting the gut microbiome, it can develop therapies that are more effective and have fewer side effects than traditional medications.

Evelo has a number of product candidates in development, including EVL201, a potential treatment for ulcerative colitis. The company's pipeline also includes therapies for other gastrointestinal diseases, as well as for autoimmune disorders and cancer. Evelo is headquartered in Cambridge, Massachusetts, and is listed on the Nasdaq Stock Market under the ticker symbol EVLO.

Evelo Biosciences is a clinical-stage biotechnology company focused on developing novel therapies for the treatment of a range of diseases by modulating the microbiome. They believe that the microbiome plays a critical role in human health and that by developing therapies that target specific aspects of the microbiome, they can improve the lives of patients suffering from chronic conditions.